Table 1.
LC-MS/MS methods for determination of one drug.
| Analyte(s) | Indication | Matrices | Prep | Solid Phase | E-M | Interf | IS | ME (%) | RT (min) | LLOQ | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nimorazole | Radiosensitizer | r-plasma | PPT | C18 (50 × 4.6 mm, 2.7 µm) | ISO | ESI(+) | AN | NEG | 1.5 | 0.25 ng/mL | [4] |
| JI-101 | Multi-kinase inhibitor | h-plasma h-urine |
SPE | C18 (50 × 2.1 mm, 5 µm) | ISO | ESI(+) | AN | 98 | 2.0 | 1.57 ng/mL 0.97 ng/mL |
[5] |
| LBH589 | HDAC inhibitor | m-plasma m-tissue |
LLE | C18 (50 × 2.1 mm, 1.7 µm) UPLC |
ISO | ESI(+) | AN | NEG | 2.0 | 2.5 ng/mL 35.7 ng/mg |
[6] |
| Vinorelbine | Vinca alkaloid | h-plasma | LLE | C18 (50 × 2.1 mm, 3 µm) | ISO | ESI(+) | AN | 95.8–106.7 | 2.0 | 0.1 ng/mL | [7] |
| Cerivastatin | Inhibitor of HMG-CoA reductase | h-plasma | LLE | C18 (100 × 3 mm, 3.5 µm) | ISO | ESI(+) | AN | NEG | 2.0 | 0.01 ng/mL | [8] |
| Osimertinib | Tyrosine kinase inhibitor | r-plasma | PPT | C18 (50 × 2.1 mm, 3 µm) | GRA | ESI(+) | AN | 90.1–97.3 | 2.5 | 1 ng/mL | [9] |
| Anastrazole | Aromatase inhibitor | h-plasma | SPE | C18 (50 × 4.6 mm, 5 μm) UPLC |
ISO | ESI(+) | AN | 97.5 | 2.5 | 0.3 ng/mL | [10] |
| SZ-685C | Marine anticancer agent | r-plasma | LLE | C18 (100 × 2.1 mm, 3 µm) | ISO | ESI(−) | AN | 94.3 | 2.5 | 5 ng/mL | [11] |
| CLR1401 | Anticancer candidate | r-plasma | LLE | C18 (50 × 3.0 mm, 5 µm) | GRA | ESI(+) | IL | 80.0–86.0 | 2.8 | 2 ng/mL | [12] |
| Veliparib (ABT-888) | PARP-1 & 2 inhibitor | h-plasma | PPT | C18 (100 × 2.1 mm, 3 µm) | ISO | ESI(+) | AN | UNK | 3.0 | 5 nmol/L | [13] |
| Docetaxel | Anticancer drug | h-plasma | LLE | C8 (50 × 2.1 mm, 5 µm) | ISO | ESI(+) | AN | UNK | 3.0 | 5 ng/mL | [14] |
| Aucubin | Natural compound | r-plasma | PPT | Diamonsil C18(2) | ISO | ESI(+) | AN | 90.8–91.0 | 3.0 | 10 ng/mL | [15] |
| HCQ | Inhibitor of autophagy | h-blood | PPT | C8 (50 × 2.1 mm, 5 µm) | ISO | ESI(+) | IL | 93.0–100.6 | 3.0 | 5 ng/mL | [16] |
| Sunitinib | Tyrosine kinase inhibitor | h-plasma | LLE | C18 (50 × 2.1 mm, 3.5 µm) | ISO | ESI(+) | AN | UNK | 3.0 | 0.2 ng/mL | [17] |
| DZNep | Methylation inhibitor | m-plasma | LLE | HILIC (100 × 2.1 mm, 1.7 µm) UPLC |
GRA | ESI(+) | AN | 84–87 | 3.0 | 5 ng/mL | [18] |
| SN-38 | Anticancer drug | h-plasma | PPT | C18 (50 × 2.0 mm, 4 µm) | GRA | ESI(+) | AN | UNK | 3.0 | 0.05 ng/mL | [19] |
| Vincristine | Anticancer drug | h-plasma | PPT | C18 (50 × 2.1 mm, 5 µm) | ISO | APCI(+) | AN | UNK | 3.0 | 0.1 ng/mL | [20] |
| MS-275 | HDAC inhibitor | h-plasma | LLE | C18(50 × 2.1 mm, 3.5 μm) | GRA | ESI(+) | AN | UNK | 3.0 | 0.5 ng/mL | [21] |
| trans-resveratrol | Natural compound | m-plasma m-brain |
LLE | C18 (100 × 1 mm, 5 μm) | ISO | ESI(−) | AN | 93.8–100.6 | 3.0 | 5 ng/mL | [22] |
| ZD6474 | Tyrosine kinase inhibitor | h-plasma h-fluid |
LLE | C18 (50 × 2.1 mm, 2.6 µm) | ISO | ESI(+) | IL | 98.0 | 3.0 | 0.25 ng/mL 0.25 ng/mL |
[23] |
| Crizotinib | Tyrosine kinase inhibitor | r-plasma | PPT | Zorbax XDB C18 (2.1 × 50 mm, 3.5 μm) |
GRA | ESI(+) | AN | 94.3–96.2 | 3.5 | 1 ng/mL | [24] |
| cabozantinib | Tyrosine kinase inhibitor | r-plasma | LLE | C18 (50 × 2 mm, 5 μm) | ISO | ESI(+) | AN | 105–115 | 3.5 | 0.5 ng/mL | [25] |
| KPS-A | Natural compound | r-plasma | PPT | C18 (2.1 × 50 mm, 3.5 μm) | GRA | ESI(+) | AN | 93–96 | 3.5 | 0.5 ng/mL | [26] |
| Clofarabine triphosphate |
Metabolite of clofarabine | h-PBMC | PPT | CN (100 × 4.6 mm, 5 μm) | GRA | ESI(+) | AN | 91–105 | 3.5 | 1.25 ng/107 cells | [27] |
| Paclitaxel | Antimicrotubule agent | r-plasma r-tissue |
LLE | C8 (50 × 2.1 mm, 5 μm) | ISO | ESI(+) | IL | 70.9–82.7 | 3.5 | 0.5 ng/mL 1.5 ng/g |
[28] |
| EDL-155 | Anticancer agent | r-plasma | PPT | C8 (50 × 2.1 mm, 3.5 μm) | GRA | ESI(+) | AN | 98.6 | 3.5 | 0.1 ng/mL | [29] |
| Henatinib | Kinase inhibitor | h-plasma h-urine |
PPT | C18 (50 × 2.1 mm, 2.5 μm) | ISO | ESI(+) | AN | 90.5–100.9 | 3.5 | 0.1 ng/mL 1 ng/mL |
[30] |
| Ceritinib | ALK inhibitor | h-plasma h-brain |
PPT | C18 (50 × 2.1 mm, 2.7 μm) | GRA | ESI(+) | IL | 92–109 | 3.6 | 1 ng/mL | [31] |
| Methergine | chemosensitizer for cancer | h-plasma | LLE | C18 (100 × 2.1 mm, 2.7 μm) | ISO | ESI(+) | AN | 61–66 | 4.0 | 0.025 ng/mL | [32] |
| Letrozole | Aromatase inhibitor | h-plasma | SPE | C18 (100 × 2.1 mm, 3.5 μm) | ISO | ESI(+) | AN | NEG | 4.0 | 0.25 ng/mL | [33] |
| Deacetyl mycoepoxydiene | Marine anticancer agent | r-plasma | PPT | C18 (150 × 2.1 mm, 5 μm) | ISO | ESI(+) | AN | 95.5–97.8 | 4.0 | 5 ng/mL | [34] |
| Sorafenib | Kinase inhibitor | h-plasma | PPT | SymmetryShield RP8 (50 × 2.1 mm, 3.5 μm) (0.1% FA:ACN) |
ISO | ESI(+) | IL | 98.6 | 4.0 | 5 ng/mL | [35] |
| QBH-196 | c-Met tyrosine kinase inhibitor | r-plasma | LLE | C18 (50 × 2.1 mm, 2.6 µm) | GRA | ESI(+) | AN | 80–115 | 4.0 | 8 ng/mL | [36] |
| Fenretinide | Chemopreventive agent | m-plasma | PPT | C18 (50 × 2.1 mm, 5 μm) | GRA | APCI(+) | AN | 100.8–108.7 | 4.5 | 0.5 ng/mL | [37] |
| PM01183 | Antineoplastic agent | Animal plasma |
SPE | C18 (30 × 2.1 mm, 3 μm) | GRA | ESI(+) | IL | 88–103 | 5.0 | 0.1 ng/mL | [38] |
| JCC76 | Antitumor agent | r-plasma | LLE | C18 (40 × 2.0 mm, 5 μm) | ISO | ESI(−) | AN | 90.8–96.9 | 5.0 | 0.3 ng/mL | [39] |
| Megestrol acetate | Hormonal therapy | h-plasma | LLE | C18 (50 × 2.0 mm, 3 µm) | ISO | ESI(+) | AN | 92.3–95.8 | 5.0 | 1.0 ng/mL | [40] |
| Berbamine | Natural compound | r-plasma | PPT | C18 (150 × 2.0 mm, 5 μm) | GRA | ESI(+) | AN | 97.2–98.5 | 5.5 | 1 ng/mL | [41] |
| Peri-plocymarin | potential anticancer agent | r-plasma r-tissue |
LLE | C18 (2.1 × 150 mm, 3.0 μm) | ISO | ESI(+) | AN | 95.8–105 | 6.0 | 0.5 ng/mL | [42] |
| ABL | potential anticancer agent | r-plasma | PPT | C18 (50 × 4.6 mm, 3.0 μm) | ISO | ESI(+) | AN | 104–108 | 6.0 | 1.6 ng/mL | [43] |
| Cisplatin | Anticancer drug | r-tissue | LLE | C18 (50 × 2.1 mm, 1.8 μm) | ISO | ESI(+) | AN | 89–104 | 6.0 | 5 ng/mL | [44] |
| EC-18 | Anticancer agent | r-plasma m-plasma |
PPT | C18 (150 × 2 mm, 4.0 μm) | GRA | ESI(+) | IL | 77.9–89.0 | 7.0 | 50 ng/mL | [45] |
| Z-endoxifen | Anti-estrogen | h-serum | PPT | C18 (150 × 2.1 mm, 2.6 µm) | GRA | ESI(+) | IL | NA | 7.0 | 1 ng/mL | [46] |
| 5-azacytidine | Anticancer agent | h-plasma | SPE | C18 (250 × 2.1 mm, 4 µm) | ISO | ESI(+) | AN | 51–55 | 7.0 | 5 ng/mL | [47] |
| RGB-286638 | Protein kinase inhibitor | h-plasma h-urine |
LLE | C18 (50 × 2.1 mm, 5 µm) | GRA | ESI(+) | IL | 146–151 | 7.0 | 2 ng/mL 2 ng/mL |
[48] |
| Azurin p28 | Anticancer peptide | m-ser | PPT | C18 (100 × 2 mm, 5 µm) | GRA | ESI(+) | AN | UNK | 7.5 | 100 ng/mL | [49] |
| Apogossypol | Bcl-2 inhibitor | m-plasma | PPT | C18 (100 × 2 mm, 4 µm) | GRA | ESI(+) | AN | UNK | 7.5 | 10 ng/mL | [50] |
| Methotrexate | Anticancer drug | h-saliva | SPE | C18 (150 × 2.0 mm, 2.2 μm) | GRA | ESI(+) | AN | 96–104 | 8.0 | 1.0 ng/mL | [51] |
| CSUOH0901 | COX-2 inhibitor | r-plasma | PPT | C18 (50 × 2.0 mm, 5 μm) | GRA | ESI(+) | AN | 90.1–94.5 | 8.0 | 0.5 ng/mL | [52] |
Abbreviations: Prep: sample preparation; S-Ph (M-Ph): Solid phase (Mobile phase); E-M: Elution mode; Interf: Interface; IS: Internal standard; RT: Run time; LLOQ: Lower limit of quantitation; Ref.: Reference number; h: human; m: mouse; r: rat; d: dog; LLE: liquid-liquid extraction; SPE: solid phase extraction; PPT: protein precipitation; ISO: isocratic elution; GRA: gradient elution; AN: analogue internal standard; IL: isotope labeled internal standard; LBH589: Panobinostat; HCQ: Hydroxychloroquine; JCC76: Cyclohexanecarboxylic acid [3-(2,5-dimethyl-benzyloxy)-4-(methanesulfonyl-methyl-amino)-phenyl]-amide; DZNep: 3-Deazaneplanocin A; EDL-155: 1,2,3,4-tetrahydroisoquinoline; ZD6474: vandetanib; PR104: (A: alcohol; H: hydroxylamine; M: amine; G: O-glucuronide); CA4P: combretastatin A4 phosphate; CA4: combretastatin A4; CA4G: combretastatin A4 glucuronide; ABL:1-O-acetylbritannilactone; KPS-A: kalopanaxsaponin A; QBH-196: N1-(3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperidin-1-yl) propoxy] quinolin-4-yloxy}phenyl)-N4-(2,4-difulurobenzylidene) semicarbazided; NA: not available; NEG: negligible matrix effect; UNK: unknown; ME: matrix effect; UPLC: Ultra-Performance Liquid Chromatography.